MANAGEMENT

 Delcath Systems Inc.

Management & Board of Directors

RICHARD TANEY, JD – Chief Executive Officer, President and Director
Mr. Taney has been a Director since November 2006, was appointed Chief Executive Officer in December 2006 and named President in April 2007. He is the founding member of T2 Capital Management, LLC, an investment management company. Prior to establishing his money management venture, he spent 20 years advising and managing assets for high net worth and institutional clients, most recently as Managing Director of Banc of America Securities. Mr. Taney is also a founding partner of Sandpiper Capital Partners, an investment partnership that focuses on private equity investments and advisory work for privately held companies involved in a variety of emerging technologies. He earned his B.A. from Tufts University and his J.D. from Temple University School of Law.

PAUL M. FEINSTEIN, ESQ – Chief Financial Officer
Mr. Feinstein has been the Chief Financial Officer since October 2003. He was named Treasurer in April 2007. From 1991 to 2002, he was Vice President of Finance for the New York Road Runners in New York City. From 1988 to 1990, he was the Controller of Mechanical Plastics, Inc. Prior to that he held senior financial positions with Holmes Protection Services, Jewelers Protection Services and Parade Publications and was with Coopers & Lybrand, the international accounting services firm that is now part of PricewaterhouseCoopers. He is licensed to practice law in New York State. He holds a B.B.A. from Pace College, an LL.M. in Taxation from New York University School of Law and graduated from Albany Law School of Union University.

MARK MORRISON, M.D., PH.D. -- Chief Medical Officer
Board Certified in Medical Oncology and Internal Medicine, Dr. Morrison brings broad experience in clinical research of both drugs and devices. Dr. Morrison earned his M.D. and Ph.D. from the Mt. Sinai School of Medicine in New York City, where his thesis explored the potential targeted therapy of melanoma. Following his internship and residency at Beth Israel Medical Center and Fellowship in Medical Oncology at Memorial Sloan-Kettering Cancer Center (MSKCC), Dr. Morrison remained as an instructor in the Clinical Immunology Service, Melanoma Group at MSKCC. Dr. Morrison began his career in the pharmaceutical industry with American Cyanamid, where he served as Clinical Team Leader, with a primary focus on the development of therapies with monoclonal antibody conjugates. He subsequently spent twelve years at Pfizer, beginning in New Product Development, where his role encompassed both clinical trial conduct and market analysis, leading to the development of comprehensive product life cycle plans for Pfizer's Oncology pipeline. Dr. Morrison then moved to the Medical Affairs division where he led the post-marketing clinical development of the chemotherapy Camptosar(TM) (irinotecan). Most recently at Pfizer, Dr. Morrison created and headed a team focused specifically on optimizing the clinical development of new drug and device products. Dr. Morrison's career also has included the position of Senior Director, Medical Affairs and Oncology Medical Section Director, overseeing strategic planning and the conduct of Oncology clinical trials to lead to regulatory approvals at i3 Research, a global Clinical Research Organization.

MR. JOHN TALARICO - Senior Vice President Regulatory Affairs And Quality Systems
Mr. Talarico recently held a similar title at Excelsior Medical and ProRhythm, Inc., manufacturers of Class II and III combination products involving a drug and device. He has held senior engineering, quality and regulatory roles at a series of medical device companies, during which time he was responsible for PMA, IDE and 510(k) submissions. Besides numerous FDA approvals, Mr. Talarico has also been successful in gaining international device approvals including the European CE Mark. He has managed worldwide clinical trials for numerous products and directed the QA, regulatory and compliance activities through approval and commercialization.

JONATHAN A. FOLTZ, CFA – Executive Vice President
Mr. Foltz has been Executive Vice President since June 2007. He had been working with Delcath in an advisory role for periods between 2001 and 2007. Mr. Foltz is a founder and Director of Os Technology, a women’s health medical device company. From 1992 to 2001, he was Director of Operations at Delcath and served as Acting Chief Operating Officer from 1999 to 2001 and Acting Chief Financial Officer from 1998 to 2000. Prior to 1992, Mr. Foltz held supervisory and analytical positions at Venkol Ventures, a healthcare-focused venture capital fund, Nicholas Lawrence & Co., a regional stock brokerage, Value Line, Inc. and Walter Heller & Co. A Chartered Financial Analyst, Mr. Foltz received a B.S. in Finance and Computer Science from Lehigh University and an MBA from the University of Connecticut.

JASON A. RIFKIN, ESQ – Vice President Business Development
Mr. Rifkin has been Vice President of Business Development since June 2007. Prior to joining Delcath, Jason practiced law at Fox Rothschild LLP, where he was an Associate in the Corporate Department - Pharmaceuticals and Biotechnology Group. There, Mr. Rifkin worked extensively on intellectual property matters, including domestic and international patent applications, and regulatory and licensing issues. Prior to that, Mr. Rifkin practiced at a boutique litigation firm in New York City, where he served as trial and appellate counsel in a wide array of cases in both federal and state courts. Mr. Rifkin holds a B.A. from the University of Pennsylvania, a J.D. from Northeastern University School of Law and an M.B. in Biotechnology from the University of Pennsylvania, School of Engineering and Applied Sciences.

HAROLD S. KOPLEWICZ, MD – Chairman of the Board
Dr. Koplewicz has been a Director since September 2006 and was appointed Chairman in February 2007. Dr. Koplewicz is the Executive Director of the Nathan S. Kline Institute for Psychiatric Research. He is only the third person to hold this title since 1952. Dr. Koplewicz is also the Arnold and Debbie Simon Professor and Chairman of the Department of Child and Adolescent Psychiatry and Professor of Pediatrics and founder of the NYU Child Study Center at the New York University School of Medicine. He has served as a member of the National Board of Medical Examiners and as a commissioner of the New York State Commission on Youth, Crime and Violence and Reform of the Juvenile Justice System.

ROBERT B. LADD, CFA – Director
Mr. Ladd has been a director since October 2006. Since January 2003, Mr. Ladd has served as the founder and managing member of Laddcap Value Advisors LLC, the general partner of Laddcap Value Partners LP. From 1998 to November 2002, Mr. Ladd served as a Managing Director for Neuberger Berman; there he served as a portfolio manager for various high net worth clients and as a securities analyst. Mr. Ladd graduated from the University of Pennsylvania’s Wharton School with a B.S. in Economics in 1980. He received his M.B.A. from Northwestern University’s Kellogg School of Management in 1983. Mr. Ladd has also earned a CFA designation.

JONATHAN J. LEWIS, MD, PhD – Director
Dr. Lewis has been a Director since June 2007. Dr. Lewis is Chief Executive Officer of ZIOPHARM Oncology, Inc. He has held leadership positions at the Memorial Sloan-Kettering Cancer Center, Yale-New Haven Hospital, Yale University School of Medicine and Cornell University Medical School. He was Chief Medical Officer of Antigenics, Inc. from 2000 to 2003. Dr. Lewis earned his MB.B.Ch. from Witwatersrand University School of Medicine (Johannesburg, South Africa) and his Ph.D. in Molecular Biology from Witwatersrand and Yale University School of Medicine. Dr. Lewis conducted his Surgical Residency at Johannesburg General Hospital, Witwatersrand University School of Medicine and at Yale-New Haven Hospital, Yale University School of Medicine. He is a Fellow of both the Royal College of Surgeons and the American College of Surgeons. Dr. Lewis was a Research Fellow in the Department of Surgery and Molecular Biophysics and Biochemistry at Yale University School of Medicine, and was a Postdoctoral Fellow in the Department of Immunology and Surgery at Memorial Sloan-Kettering Cancer Center.

LAURA A. PHILIPS, PhD, MBA – Director
Dr. Philips has been a Director since May 2007. Dr. Philips currently serves as Chair of the Board of Directors of Planned Parenthood of New York City, and serves on the Board of Directors of Boyce Thompson Institute. From 2003 to 2006, she was Chief Operating Officer and Acting Chief Financial Officer of NexGenix Pharmaceuticals. Prior to that, she was Vice President, Program Management for the AMDeC Foundation. Dr. Philips worked at Corning Incorporated from 1997 to 2002, where she held several positions including Program Director of the Fuel Cells Division. From 1994 to 1996, Dr. Philips held various government positions in Washington, D.C., most recently in a Presidential appointment as Senior Policy Advisor to Secretary of Commerce Ronald Brown. Dr. Philips was on the faculty of Cornell University in the Department of Chemistry from 1987 to 1994 and was an NIH Post-Doctoral Fellow at the University of Chicago. She received a B.A. in Chemistry from Williams College, a Ph.D. in Physical Chemistry from the University of California Berkeley and an MBA with Distinction from Cornell University's Johnson School of Management.